Structural and antigenic variance between novel influenza A/H1N1/2009 and influenza A/H1N1/2008 viruses. 2009

Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
Centre for Cellular and Molecular Biology, Hyderabad 500 007, India. shailen@ccmb.res.in

BACKGROUND The emergence of influenza A/H1N1/2009 is alarming. The severity of previous epidemics suggests that the susceptibility of the human population to H1N1 is directly proportional to the degree of changes in hemagglutinin/HA and neuraminidase/NA; therefore, H1N1/2009 and H1N1/2008 were analyzed for their sequence as well as structural divergence. METHODS The structural and sequence divergence of H1N1/2009 and H1N1/2008 strains were analyzed by aligning HA and NA amino acid sequences by using ClustalW and ESyPred3D software. To determine the variations in sites of viral attachment to host cells, a comparison between amino acid sequences of HA and NA glycosylation sites was performed with NetNGlyc software. The antigenic divergence was executed by CTL epitope prediction method. RESULTS The amino acid homology levels of H1N1/2009 were 20.32% and 18.73% compared to H1N1/2008 for HA and NA genes, respectively. In spite of the high variation in HA and NA amino acid composition, there was no significant difference in their structures. Antigenic analysis proposes that great antigenic differences exist between both the viral strains, but no addition of a new site of glycosylation was observed. CONCLUSIONS To our knowledge, this is the first report suggesting that the circulating novel influenza virus A/H1N1/2009 attaches to the same glycosylation receptor sites as its predecessor influenza A/H1N1/2008 virus, but is antigenically different and may have the potential for initiating a significant pandemic. Our study may facilitate the development of better therapeutics and preventive strategies, as well as impart clues for novel H1N1 diagnostic and vaccine development.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D006031 Glycosylation The synthetic chemistry reaction or enzymatic reaction of adding carbohydrate or glycosyl groups. GLYCOSYLTRANSFERASES carry out the enzymatic glycosylation reactions. The spontaneous, non-enzymatic attachment of reducing sugars to free amino groups in proteins, lipids, or nucleic acids is called GLYCATION (see MAILLARD REACTION). Protein Glycosylation,Glycosylation, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000940 Antigenic Variation Change in the surface ANTIGEN of a microorganism. There are two different types. One is a phenomenon, especially associated with INFLUENZA VIRUSES, where they undergo spontaneous variation both as slow antigenic drift and sudden emergence of new strains (antigenic shift). The second type is when certain PARASITES, especially trypanosomes, PLASMODIUM, and BORRELIA, survive the immune response of the host by changing the surface coat (antigen switching). (From Herbert et al., The Dictionary of Immunology, 4th ed) Antigen Switching,Antigenic Diversity,Variation, Antigenic,Antigen Variation,Antigenic Switching,Antigenic Variability,Switching, Antigenic,Diversity, Antigenic,Switching, Antigen,Variability, Antigenic,Variation, Antigen
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
December 2015, Microbial pathogenesis,
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
July 2011, Journal of clinical microbiology,
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
July 2009, Science (New York, N.Y.),
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
November 2009, Minnesota medicine,
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
October 2019, Pathogens (Basel, Switzerland),
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
September 2010, JAMA,
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
October 1983, MMWR. Morbidity and mortality weekly report,
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
August 1986, MMWR. Morbidity and mortality weekly report,
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
January 2010, Antiviral therapy,
Shailendra K Saxena, and Niraj Mishra, and Rakhi Saxena, and M L Arvinda Swamy, and Pranshu Sahgal, and Shailja Saxena, and Shrish Tiwari, and Asha Mathur, and Madhavan P Nair
December 1989, The Journal of general virology,
Copied contents to your clipboard!